Monitoring trough voriconazole plasma concentrations in haematological patients: Real life multicentre experience

Mycoses

Volumn 55, Issue 6, 2012, Pages 483-492

  Racil, Zdenek ^a,d   Winterova, Jana ^a   Kouba, Michal ^b   Zak, Pavel ^c   Malaskova, Ludmila ^a   Buresova, Lucie ^d   Toskova, Martina ^a   Lengerova, Martina ^a   Kocmanova, Iva ^a   Weinbergerova, Barbora ^a   Timilsina, Shira ^a   Rolencova, Monika ^a   Cetkovsky, Petr ^b   Mayer, Jiri ^a,d  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Haematological malignancy; Plasma concentration; Voriconazole

Indexed keywords

ECHINOCANDIN; OMEPRAZOLE; VORICONAZOLE;

ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPERGILLOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84867568482     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02186.x     Document Type: Article

References (31)

1. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100.
2. Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644-50.
3. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
4. Cordonnier C, Rovira M, Maertens J et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762-8.
5. Torres A, Serrano J, Rojas R et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol 2010; 84: 271-3.
6. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
7. Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16: 927-33.
8. Ueda K, Nannya Y, Kumano K et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89: 592-9.
9. Troke PF, Hockey HP, Hope WW. The clinical efficacy of voriconazole and its relationship to plasma concentrations in patients: an observational study. Antimicrob Agents Chemother 2011; 55: 4782-8.
10. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56(Suppl. 1): 17-23.
11. Scott LJ, Simpson D. Voriconazole : a review of its use in the management of invasive fungal infections. Drugs 2007; 67: 269-98.
12. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-63.
13. Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-5.
14. Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. Arch Dis Child 2008; 93: 578-81.
15. Wood N, Tan K, Purkins L et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56(Suppl. 1): 56-61.
16. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009; 53: 1793-6.
17. Trifilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509-13.
18. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
19. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
20. Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348-50.
21. Perea JR, Diaz De Rada BS, Quetglas EG, Juarez MJ. Oral versus intravenous therapy in the treatment of systemic mycosis. Clin Microbiol Infect 2004; 10(Suppl. 1): 96-106.
22. Lee S, Kim BH, Nam WS et al. Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers. J Clin Pharmacol 2012; 52: 195-203.
23. Alvarez-Lerma F, Allepuz-Palau A, Garcia MP et al. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother 2008; 20: 93-100.
24. Han K, Capitano B, Bies R et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2010; 54: 4424-31.
25. Mohammedi I, Piens MA, Padoin C, Robert D. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis 2005; 24: 358-60.
26. Miyakis S, van Hal SJ, Solvag CJ, Ray J, Marriott D. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. Ther Drug Monit 2010; 32: 661-4.
27. Han K, Bies R, Johnson H, Capitano B, Venkataramanan R. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. Clin Pharmacokinet 2011; 50: 201-14.
28. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2.
29. Baddley JW, Andes DR, Marr KA et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-67.
30. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med wkly 2006; 136: 739-42.
31. Weiler S, Fiegl D, MacFarland R et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55: 925-8.